Literature DB >> 26456767

Understanding chronic neutropenia: life is short.

Marije Bartels1, Kate Murphy1, Ester Rieter1, Marrie Bruin1.   

Abstract

The pathophysiological mechanisms underlying chronic neutropenia are extensive, varying from haematopoietic stem cell disorders resulting in defective neutrophil production, to accelerated apoptosis of neutrophil progenitors or circulating mature neutrophils. While the knowledge concerning genetic defects associated with congenital neutropenia or bone marrow failure is increasing rapidly, the functional role and consequences of these genetic alterations is often not well understood. In addition, there is a large group of diseases, including primary immunodeficiencies and metabolic diseases, in which chronic neutropenia is one of the symptoms, while there is no clear bone marrow pathology or haematopoietic stem cell dysfunction. Altogether, these disease entities illustrate the complexity of normal neutrophil development, the functional role of the (bone marrow) microenvironment and the increased propensity to undergo apoptosis, which is typical for neutrophils. The large variety of disorders associated with chronic neutropenia makes classification almost impossible and possibly not desirable, based on the clinical phenotypes. However, a better understanding of the regulation of normal myeloid differentiation and neutrophil development is of great importance in the diagnostic evaluation of unexplained chronic neutropenia. In this review we propose insights in the pathophysiology of chronic neutropenia in the context of the functional role of key players during normal neutrophil development, neutrophil release and neutrophil survival.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  bone marrow; genetic defects; neutropenia; neutrophils

Mesh:

Year:  2015        PMID: 26456767     DOI: 10.1111/bjh.13798

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  The Mitochondrial Transacylase, Tafazzin, Regulates for AML Stemness by Modulating Intracellular Levels of Phospholipids.

Authors:  Ayesh K Seneviratne; Mingjing Xu; Juan J Aristizabal Henao; Val A Fajardo; Zhenyue Hao; Veronique Voisin; G Wei Xu; Rose Hurren; S Kim; Neil MacLean; Xiaoming Wang; Marcela Gronda; Danny Jeyaraju; Yulia Jitkova; Troy Ketela; Michael Mullokandov; David Sharon; Geethu Thomas; Raphaël Chouinard-Watkins; James R Hawley; Caitlin Schafer; Helen Loo Yau; Zaza Khuchua; Ahmed Aman; Rima Al-Awar; Atan Gross; Steven M Claypool; Richard P Bazinet; Mathieu Lupien; Steven Chan; Daniel D De Carvalho; Mark D Minden; Gary D Bader; Ken D Stark; Paul LeBlanc; Aaron D Schimmer
Journal:  Cell Stem Cell       Date:  2019-03-28       Impact factor: 24.633

2.  Elastase inhibitors as potential therapies for ELANE-associated neutropenia.

Authors:  Vahagn Makaryan; Merideth L Kelley; Breanna Fletcher; Audrey Anna Bolyard; A Andrew Aprikyan; David C Dale
Journal:  J Leukoc Biol       Date:  2017-07-28       Impact factor: 4.962

3.  Dissecting ELANE neutropenia pathogenicity by human HSC gene editing.

Authors:  Shuquan Rao; Yao Yao; Josias Soares de Brito; Qiuming Yao; Anne H Shen; Ruth E Watkinson; Alyssa L Kennedy; Steven Coyne; Chunyan Ren; Jing Zeng; Anna Victoria Serbin; Sabine Studer; Kaitlyn Ballotti; Chad E Harris; Kevin Luk; Christian S Stevens; Myriam Armant; Luca Pinello; Scot A Wolfe; Roberto Chiarle; Akiko Shimamura; Benhur Lee; Peter E Newburger; Daniel E Bauer
Journal:  Cell Stem Cell       Date:  2021-01-28       Impact factor: 24.633

4.  Molecular Mechanisms for Regulation of Neutrophil Apoptosis under Normal and Pathological Conditions.

Authors:  E M Noseykina; I A Schepetkin; D N Atochin
Journal:  J Evol Biochem Physiol       Date:  2021-07-01       Impact factor: 0.444

5.  Assessment of Neutrophil Chemotaxis Upon G-CSF Treatment of Healthy Stem Cell Donors and in Allogeneic Transplant Recipients.

Authors:  Anna Thunström Salzer; Maria J Niemiec; Ava Hosseinzadeh; Marios Stylianou; Fredrik Åström; Marc Röhm; Clas Ahlm; Anders Wahlin; David Ermert; Constantin F Urban
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.